Navigation Links
GeoPharma to Present at EdgeWater Research Partners Conference
Date:4/8/2008

Largo, Fla., April 8, 2008 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) announced that the company will present today at the EdgeWater Research Partners Spring Conference being held at the Grand Hyatt in Denver, Colorado at 2:25 MT.

"We are thoroughly pleased to have GeoPharma present at the spring conference," said EdgeWater President David Lavigne. "GeoPharma has a unique story with a thriving Manufacturing and Distribution business. We expect further positive developments in their Specialty Pharma business with several antibiotic drugs soon to enter into production. Furthermore, the continued development of their Early Stage Ovarian Cancer Diagnostic Device and the value it may add if approved, has not been factored into their current valuation."

EdgeWater Research Partners recently issued a Quarterly update to their Initial Coverage Report on GeoPharma which is currently the featured report on the GeoPharma website. The EdgeWater report and other research reports can be found on the Investor Relations Home Page at http://www.GeoPharmainc.com .

ABOUT EDGEWATER RESEARCH PARTNERS LLC:

EdgeWater Research Partners LLC. is an independent subscription based micro cap stock research company. Subscribers receives a monthly micro cap stock newsletter, in addition to individual company research reports and updates similar to the one's issued on GeoPharma. Annual subscriptions to EdgeWater Research services are available at http://www.edgewaterresearch.com

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the GeoPharma website at http://www.GeoPharmainc.com.

FORWARD-LOOKING STATEMENTS

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoPharma Announces Record Revenues in Third Quarter Results
2. GeoPharma Announces Third Quarter Conference Call
3. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
4. MaxCyte to Present at BIO-Europe Spring 2008 Conference
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Prometic to present at the American Chemical Society
7. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
8. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
11. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
Breaking Biology Technology:
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):